Related references
Note: Only part of the references are listed.Rapid progression of familial amyloidotic polyneuropathy A multinational natural history study
David Adams et al.
NEUROLOGY (2015)
Liver Transplantation for Hereditary Transthyretin Amyloidosis: After 20 Years Still the Best Therapeutic Alternative?
Bo-Goran Ericzon et al.
TRANSPLANTATION (2015)
Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial
Kevin Fitzgerald et al.
LANCET (2014)
Effect on disability and safety of Tafamidis in late onset of Met30 transthyretin familial amyloid polyneuropathy
P. Lozeron et al.
EUROPEAN JOURNAL OF NEUROLOGY (2013)
Repurposing Diflunisal for Familial Amyloid Polyneuropathy A Randomized Clinical Trial
John L. Berk et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy
Teresa Coelho et al.
JOURNAL OF NEUROLOGY (2013)
Safety and Efficacy of RNAi Therapy for Transthyretin Amyloidosis
Teresa Coelho et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Tafamidis for transthyretin familial amyloid polyneuropathy A randomized, controlled trial
Teresa Coelho et al.
NEUROLOGY (2012)
Long-term survival after liver transplantation in patients with familial amyloid polyneuropathy
T. Yamashita et al.
NEUROLOGY (2012)
Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: Prediction and prevention
Janos Szebeni et al.
ADVANCED DRUG DELIVERY REVIEWS (2011)
Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met30)
Gösta Holmgren et al.
CLINICAL GENETICS (2010)
Targeted Delivery of RNAi Therapeutics With Endogenous and Exogenous Ligand-Based Mechanisms
Akin Akinc et al.
MOLECULAR THERAPY (2010)
Progression of transthyretin amyloid neuropathy after liver transplantation
Juris J. Liepnieks et al.
NEUROLOGY (2010)
Cardiac amyloidosis in African Americans: Comparison of clinical and laboratory features of transthyretin V122I amyloidosis and immunoglobulin light chain amyloidosis
Lawreen H. Connors et al.
AMERICAN HEART JOURNAL (2009)
Liver Transplantation for Familial Amyloidotic Polyneuropathy: Impact on Swedish Patients' Survival
Sadahisa Okamoto et al.
LIVER TRANSPLANTATION (2009)
Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates
Maria Frank-Kamenetsky et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Natural history and outcome in systemic AA amyloidosis
Helen J. Lachmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Transthyretin and familial amyloidotic polyneuropathy - Recent progress in understanding the molecular mechanism of neurodegeneration
Xu Hou et al.
FEBS JOURNAL (2007)
Progressive wild-type transthyretin deposition after liver transplantation preferentially occurs onto myocardium in FAP patients
M. Yazaki et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2007)
RNAi-mediated gene silencing in non-human primates
TS Zimmermann et al.
NATURE (2006)
Contribution of wild-type transthyretin to hereditary peripheral nerve amyloid
M Yazaki et al.
MUSCLE & NERVE (2003)
Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy
HJ Lachmann et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells
SM Elbashir et al.
NATURE (2001)
The course and prognostic factors of familial amyloid polyneuropathy after liver transplantation
D Adams et al.
BRAIN (2000)
Share Paper
